|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
Choosing a Biotech Stock 3: Biogen Idec [September 14, 2007 blog]
Rituxan and Zevalin, A Cautionary Tale [July 14, 2007 at New York Times, registration required]
Biogen Idec and Tysabri [May 6, 2007 blog]
Next conference date: July 22, 2008 @ 5:30 AM Pacific Time
2008 |
|||
 |
|
||
04/23/2008 |
07/22/2008 |
||
Q1 |
Q2 |
||
2007 |
|||
|
|
|
|
02/06/2008 |
10/23/2007 |
07/24/2007 |
05/02/2007 |
Q4 |
Q3 |
Q2 |
Q1 |
2006 |
|||
|
|
|
|
02/15/2007 |
10/31/2006 |
07/26/2006 |
04/26/2006 |
Q4 |
Q3 |
Q2 |
Q1 |
First acquired on February 6, 2008 Biogen-Idec is a biotechnology pharmaceutical company which markets Rituxan, Zevalin, Avonex, Fumaderm, and Tysabri.
Biogen-Idec Web site:
Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. Before making or terminating an investment you should always verify any factual basis of your decision.